Industry

Glaukos to Showcase Innovative Ophthalmic Technologies at ASCRS 2026

Eyewire+6h ago2 min read

Glaukos announced that its latest technologies will be featured across multiple scientific sessions at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, taking place April 10-13, 2026, in Washington, D.C. The company will exhibit its portfolio of products and pipeline innovations at booth #407. In addition to its exhibition presence, Glaukos will sponsor an educational symposium in partnership with ASCRS and EyeWorld titled, “Introducing Epioxa, the first and only FDA-approved, epithelium-on, oxygen-enriched corneal cross-linking treatment.” The session is scheduled for Friday, April 10, from 12:00–1:00 p.m. ET in Room 102 AB at the Walter E. Washington Convention Center. The symposium will be moderated by Brandon D. Ayres, MD, and feature a panel of experts including Kenneth A. Beckman, MD; Maanasa Indaram, MD; and Matt Jensen, MBA. The program will highlight clinical insights and advancements in corneal cross-linking therapies, particularly focusing on the newly approved Epioxa treatment. Scientific Presentations Highlight Pipeline and Clinical Progress Glaukos-supported research will also be presented in several key sessions throughout the meeting, emphasizing advancements in glaucoma and corneal health: Saturday, April 11 1:40–1:45 p.m. — Arkadiy Yadgarov, MD: 12-Month Outcomes of Standalone Third-Generation Trabecular Micro-Bypass Stents in Eyes with Open-Angle Glaucoma 2:01–2:06 p.m. — Michael B. Raizman, MD: Design Review and Clinical Plan for Novel Keratoconus Screening Device Sunday, April 12 1:40–1:45 p.m. — Jasmin Kaur / Savak Teymoorian, MD: 12-Month Single-Center Outcomes of Travoprost Intracameral Implant in Eyes with Open-Angle Glaucoma or Ocular Hypertension 3:35–3:40 p.m. — Lisa K. Feulner, MD: Real-World Outcomes of Combining Trabecular Micro-Bypass Stents with Intracameral Travoprost Implant or Cataract Surgery On-Demand Posters Showcase Additional Clinical Data A series of on-demand poster presentations will further detail clinical outcomes and safety data related to Glaukos technologies. Topics include the durability of epithelium-on corneal cross-linking, combination therapies involving trabecular micro-bypass stents and travoprost implants, and long-term outcomes in glaucoma patients undergoing minimally invasive procedures. Contributing authors include Kenneth A. Beckman, MD; John P. Berdahl, MD; Christine N. Funke, MD; Steven R. Sarkisian Jr., MD; and Zachary D. Vest, MD. Abstracts and additional meeting information are available through the official ASCRS annual meeting website.

Read full article on Eyewire+

AI Summary

Quick Take

Glaukos is set to showcase its expanded portfolio at ASCRS 2026, headlined by the introduction of Epioxa, the first FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment. The company will also present 12-month clinical data on its third-generation trabecular micro-bypass stents and the intracameral travoprost implant, reinforcing its push toward sustained-release and minimally invasive interventional therapies.

Why It Matters

The shift toward 'epi-on' cross-linking with Epioxa marks a major milestone in corneal health, potentially offering a safer, more comfortable alternative to traditional epithelial debridement for keratoconus patients. Meanwhile, the focus on combining micro-bypass stents with sustained-release medication like iDose TR highlights the industry's aggressive move toward 'interventional glaucoma' to solve the perennial problem of patient non-compliance with topical drops. For practice owners, these developments signal a maturing market for multi-modal surgical treatments that can be performed alongside or independent of cataract surgery.

Key Details

Introduction of Epioxa, the first FDA-approved epithelium-on corneal cross-linking (CXL) system that utilizes oxygen enrichment.
Presentation of 12-month outcomes for standalone third-generation trabecular micro-bypass stents in open-angle glaucoma eyes.
Release of 12-month single-center data and real-world combination outcomes for the intracameral travoprost implant (iDose TR).
Unveiling of the design review and clinical plan for a novel keratoconus screening device aimed at earlier diagnosis.
Scientific sessions featuring expert panels on the clinical integration of oxygen-enriched CXL and the durability of 'epi-on' procedures.

Practice Implications

Surgeons should monitor the 12-month data for third-generation stents to determine if standalone placement is becoming a more viable primary intervention for open-angle glaucoma. Additionally, the availability of an FDA-approved 'epi-on' CXL treatment may require practices to update their keratoconus protocols to include oxygen-enriched therapies, which could reduce recovery times and post-operative complications compared to 'epi-off' methods.

Who's Affected

OphthalmologistsCornea SpecialistsGlaucoma SpecialistsRefractive SurgeonsPractice Owners

What's Next

Following the ASCRS 2026 meeting in April, the focus will shift to the commercial rollout of Epioxa and the further clinical validation of the 'stent-plus-implant' combination therapy. The novel keratoconus screening device is expected to move into its next phase of clinical planning following the design review presented at the meeting.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.